ImmUniverse partners attend international conferences in May

13th International Symposium on Minimal Residual Cancer
From 2nd to 4th of May 2023 more than 450 delegates and exhibitors from 26 countries attended the 13th International Symposium on Minimal Residual Cancer (ISMEC). The programme focussed on “Minimal Residual Cancer as Target of Immunotherapy and Liquid Biopsy Diagnostics”. The Institute of Tumor Biology at the University Medical Center Hamburg-Eppendorf and the European Liquid Biopsy Society hosted the meeting in Hamburg, Germany. The symposium featured eight scientific sessions and more than 30 oral and 130 ePoster presentations.

ImmUniverse partner AIT Austrian Institute of Technology GmbH contributed with an ePoster entitled “Liquid biopsy beyond cancer – circulating epigenetic biomarkers in cardiovascular and immune-mediated diseases.” On the poster they introduced the goals and multi-omics biomarker concept of ImmUniverse including first preliminary results obtained from DNA methylation and microRNA profiling on retrospective atopic dermatitis and ulcerative colitis bio samples. They further showcased the power and wide applicability of liquid biopsy based multi-omics biomarker discovery and validation by presenting epigenetic biomarker candidates. These biomarkers were identified for both the prediction of coronary artery plaque formation and type 2 diabetes diagnosis studying DNA methylation as well as miRNA profiles in blood, saliva as well as thereof derived extracellular vesicles.

For 2025, the 14th ISMRC is planned to take place in Nice, France.

Digestive Disease Week 2023
From 6th to 9th of May 2023 the Digestive Disease Week® (DDW2023) took place in Chicago, Illinois. DDW is the world’s leading educational forum for academicians, clinicians, researchers and trainees working in gastroenterology, hepatology, gastrointestinal endoscopy, gastrointestinal surgery and related fields.

Samuel Elias Pineda Chavez of Humanitas University gave insights into his research on “Low-Intensity Pulsed Ultrasound (LIPUS) as a new approach of gut disruptive liquid biopsy to boost the release of mucosal extracellular vesicles in ulcerative colitis”. The teams from Humanitas University and Scuola Superiore Sant’Anna proved that LIPUS is a safe and non-pro-inflammatory approach in experimental models of ulcerative colitis.

Florian Tran, a clinician scientist working at Kiel University, presented the poster entitled “Symptom-based disease trajectories identify a population of early super-responders in ulcerative colitis achieving complete disease control under therapy with biologics”. He shared results from the clinical trajectory analysis from the Kiel cohort, a collaborative effort within ImmUniverse and 3TR.

The next congress is already scheduled: join in Washington, D.C. for DDW2024 from 18th to 24th of May 2024.

Annual Meeting of the International Society for Extracellular Vesicles
Samuel Elias Pineda Chavez of Humanitas University presented a poster entitled “In vitro validation of Low-Intensity Pulsed Ultrasound (LIPUS) as an approach to enhance the release of microvesicles in Ulcerative Colitis patients” at the ISEV Annual Meeting 2023. The conference took place from 17th to 21st of May 2023 in Seattle, Washington.

The International Society for Extracellular Vesicles (ISEV) is the leading professional society for researchers and scientists involved in the study of microvesicles and exosomes. With more than 1,000 attendees, ISEV2023 featured presentations from the top researchers in the field, as well as providing opportunities for talks from students and early career researchers.

The ISEV2024 Annual Meeting will take place from 8th to 12th May 2024 in Melbourne, Australia.

Samuel Elias Pineda Chavez from Humanitas University presenting ImmUniverse results on Low-Intensity Pulsed Ultrasound (LIPUS)